ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0283

The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)

Nobuyuki Yajima1, Toshihiro Matsui2 and Shigeto Tohma3, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2NHO Sagamihara National Hospital, Kanagawa, Japan, 3National Hospital Organization Tokyo National Hospital, Dallas, TX

Meeting: ACR Convergence 2022

Keywords: Anti-TNF Drugs, Economics, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these medications are expensive. Furthermore, the debate regarding criteria for discontinuation of biologics continues, and at this time there are no clear criteria for discontinuation, and they often continue. Therefore, at present, high medical costs will be required for a long time. Recently, the concept of “financial toxicity,” which refers to the impact of the financial burden of treatment on lifestyle, has been proposed and is treated in the same way as physical treatment-related toxicity. Financial toxicity studies on RA have not yet been conducted. In the present study, we hypothesized that financial toxicity would be exacerbated by the use of expensive bDMARDs and JAKi and examined whether bDMARDs and JAKi exacerbate financial toxicity in RA patients.

Methods: A cross-sectional study using the NinJa database conducted at 49 sites in 2020, a database of RA patients in Japan collected from April 1, 2020 to March 31, 2021. Exposure was defined as the usage of bDMARDs or JAKi.

Outcome measure was a financial toxicity and was measured using COmprehensive Score for financial Toxicity (COST). This scale is a patient reported outcome measure (PROM) consisting of 11 items. The responses are recorded on 5-point Likert Scales (ranging from 0 = strongly disagree to 4 = strongly agree). The score by domains ranges from 0 to 44. Higher scores indicated better results and lower financial toxicity. We analyzed the association between the usage of bDMARDs or JAKi and financial toxicity by multiple regression analysis, in which the adjusted variables were age, gender, DAS28-CRP, years of disease, type of work. We used multiple imputation to deal with missing values.

Results: Of 15553 patients, we excluded 12522 patients with missing COST questionnaire data, 2 patients with missing the usage of bDMARDs or JAKi. 165 patients who the co-payment rates are 0%, 59 patients who did not use of DMARDs. A total of 1579 patients were included in the final analysis. The median age of the patients was 69 years (IQR, 57 to 77), and 79.4% were female. The median disease duration was 12 years (IQR, 6 to 20), the median DAS28-CRP was 1.95 (IQR, 1.38 to 2.64). The median copayment amount was ¥1747.1 (USD 1474.1) per month (IQR ¥589.0 [USD 4.53] to ¥11418.8 [USD 87.77]). The median COST score was 26 (IQR 22-30). The usage of bDMARDs or JAKi have a significant effect on financial toxicity in multivariable linear regression model adjusted for age, sex, disease activity (DAS28-CRP), work status, cancer onset within one-year, (coefficient -1.98, 95% Confidence Interval (CI), -2.63 to -1.33, p < 0.001).

Conclusion: The usage of bDMARDs or JAKi was associated with financial toxicity. This research may lead to the revitalization of research in medical economics in the field of collagen disease, and may lead to a practice that is aware of medical cost and can develop into a practice that is willing to discuss cost issues with its patients.


Disclosures: N. Yajima, None; T. Matsui, AbbVie/Abbott, Pfizer, Asahi Kasei Pharma, Astellas Pharm Inc, Chugai Pharmaceutical, Eisai, Mitsubishi-Tanabe Pharma, Taisho Pharmaceutical, Daiichi Sankyo, Eli Lilly, Ono Pharmaceutical, Takeda Pharmaceutical, UCB; S. Tohma, Pfizer, Mitsubishi-Tanabe Pharma, Daiichi Sankyo, Chugai Pharmaceutical, AbbVie/Abbott, Ono Pharmaceutical, Takeda Pharmaceutical, Astellas Pharm, Ayumi Pharmaceutical, QIAGEN K.K, Asahi Kasei Pharma.

To cite this abstract in AMA style:

Yajima N, Matsui T, Tohma S. The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-association-between-the-usage-of-biological-disease-modified-anti-rheumatic-drug-or-jak-inhibitor-and-the-burden-of-treatment-costs-on-daily-life-financial-toxicity-in-ra-patients-a-cross-secti/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-the-usage-of-biological-disease-modified-anti-rheumatic-drug-or-jak-inhibitor-and-the-burden-of-treatment-costs-on-daily-life-financial-toxicity-in-ra-patients-a-cross-secti/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology